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Abstract
The first cellular response to a carcinogen is a cell cycle arrest program that may end in a permanent arrest with 
features of cellular senescence. This may be an evolutionary conserved response to delay environmental-induced 
cancer until the replicative life of the organism has ended. With the concomitant alteration of genes involved in 
cellular senescence, which promotes cellular immortalization, a further carcinogenic insult may increase the chances 
of tumorigenesis and the development of a malignant clone. Therefore, understanding cellular senescence and how it 
can be modified by environmental carcinogens, including food, may be essential for controlling the increase of cancer 
prevalence.
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Carcinogenesis
Carcinogens are widespread in nature. Humans and animals 
have been exposed to carcinogens for millions of years, both those 
in the external environment, including food, and those generated 
endogenously. It has been estimated that 80-90% of human tumors are 
generated by exposure to carcinogens, both environmental (chemicals, 
viruses, and non-ionizing and ionizing radiation) and endogenous 
(including reactive oxygen species from metabolism) [1,2].
Cancer development in humans and animals as a result of 
environmental factors, chemicals, viruses, radiation, and diet is a 
long process, requiring a large portion (from a third to half) of the 
lifespan of the organism [1,2]. There have been many hypotheses to 
explain this delayed carcinogenic effect, including the dominant role 
for immunological surveillance, first suggested by Thomas in 1959 
[3,4], and tumor dormancy [5]. It is now understood that several 
mutations need to accumulate in different hallmarks to result in a full 
tumorigenic phenotype, including mutations responsible for avoiding 
immunological surveillance [6,7]. Initiation with one of many different 
carcinogens should be followed by the spontaneous or autonomous 
proliferation of cells intended to form a tumor. However, the autonomous 
or semiautonomous growth of initiated cells only occurs late in the 
carcinogenic process. Focal lesions with autonomous cell proliferation 
can only be observed after large doses of carcinogens and much longer 
periods of exposure than that required for initiation. In fact, virtually 
every chemical carcinogen is an inhibitor of cell proliferation [8,9]. 
Haddow has suggested that the inhibition of cell proliferation could be 
an early effect of carcinogens and that in such an environment, resistant 
cells might arise and be encouraged to proliferate [10]. The growth 
of rare altered cells leading to focal neoplasms is a key phenomenon 
in the promotion of cancer development in virtually all experimental 
carcinogenesis models and in many human systems [1,6].
In most instances of cancer development in humans or animals 
in which a precursor cell population or a lesion has been identified or 
proposed, the “preneoplastic” and “precancerous” changes are always 
focal and often clonal, involving only a very small number of altered 
cells [1,11,12]. 
Different chemical agents, both mutagens and non-mutagens, have 
been shown to induce cellular senescence. Treatment of primary cells 
with high doses of radiation and other DNA-damaging agents results 
in senescence [13]. Similar effects were obtained after treatment with 
H2O2 or other reactive oxygen species [13-16]. Interestingly, the 
treatment of various tumor cell lines with different chemotherapeutic 
agents, radiation, or differentiating agents also induces irreversible 
growth arrest, with features similar to cellular senescence [17]. Moderate 
doses of doxorubicin induced a senescent phenotype in 11 out of 14 
tumor cell lines, independent of p53 status [18]. A similar effect has 
been observed in cell lines derived from human tumors treated with 
cisplatin [19], hydroxyurea [20] and bromodeoxyuridine [21] which 
are all DNA-damaging agents. The propensity of tumor cells to undergo 
senescence in response damage induced by commonly used chemicals 
was compared in cell lines with various origins [17]. Under equitoxic 
doses, the strongest induction of a senescent phenotype was observed 
with DNA-interacting agents (doxorubicin, aphidicolin, and cisplatin) 
and the weakest effect was observed with microtubule-targeting drugs 
(taxol and vincristine). A moderate response was observed with ionizing 
radiation, cytarabine, and etoposide. The induction of senescence by 
the drugs was dose dependent and correlated with the growth arrest 
observed in culture [13,20-22]. Drug-induced senescent phenotypes 
have been confirmed in vivo ([23-25] and references therein). 
Since the early 80s and the seminal work of Newbold et al. [26,27], 
cellular senescence has been viewed as a barrier to tumorigenesis. These 
and other authors have shown that it is necessary to bypass senescence 
to initiate immortal and/or tumoral clones from a naïve culture. They 
estimated that the efficacy of carcinogens that produced these clones 
was greatly increased (Table 1).
However, despite the highly increased ratio of immortalization, the 
vast majority of cells remain non-proliferative, and they most probably 
have entered carcinogenic-induced senescence. The molecular analysis 
of immortal clones shows alterations, either structural or epigenetic, in 
the genes involved in cellular senescence [28-34]. It is thought that these 
alterations are caused directly by carcinogens. This may lead to biased 
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identification. Only carcinogens able to alter cellular proliferation 
in parallel with causing immortalization will produce tumors which 
include unspecific mutagens or genome epigenetic modifiers.
Thus, it seems that the first response to a “mutagenic stress” may 
be the induction of cellular senescence. The cell becomes immortal 
only when this physiological barrier is inactivated and then a focal 
clone that can give rise to a tumor is initiated. We can speculate that 
cellular senescence is an evolutionary barrier developed to delay 
environmentally induced tumorigenesis until the replicative lifespan of 
the individual has ended. 
We can suggest, therefore, that cellular senescence is the 
first response to environmental carcinogens. We also argue that 
inhibition of such cellular senescence process will trigger a much 
higher immortalization effect, and therefore carcinogenic, for many 
environmental carcinogens. As mentioned above, many agents acting 
on diverse mechanisms have been reported to act inducing senescence 
in a variety of cell types (Table 2).
Cellular Senescence
Cellular senescence is a unique state of irreversible proliferative 
quiescence and terminal differentiation and is characterized by changes 
in transcription, chromatin conformation, cytoplasmic and nuclear 
morphology, and DNA damage signaling and a strong increase in the 
secretion of pro-inflammatory cytokines [35-37]. Senescence is the 
first line of defense against potentially transformed cells that remain 
in a state of permanent proliferative stop [30,38,39]. Progression 
to malignancy correlates with a bypass of cellular senescence [40]. 
Senescence has been observed in vitro and in vivo in response to various 
stimuli, including oncogenic stress [41,42], oxidative stress [43], and 
chemotherapeutic agents [17,25]. Cells with cellular and molecular 
characteristics of senescence have been found to be associated with 
the activation of oncogenes and the inactivation of tumor suppressor 
genes in precancerous benign neoplasms in both humans and in 
animal models [44-47]. For example, human nevis are clonal neoplasms 
containing benign melanocytes senescent through activation of the 
oncogene B-RAF [46]. In some mouse models, the inactivation of 
senescence effectors in parallel to oncogenic activation results in 
cancerous growth progression instead of benign tumors [24,44,48,49]. 
Senescence activation can be considered to be a cellular response to 
cell damage and is an attempt to address impaired tissue homeostasis. 
Thus, senescence inhibits the activation of the tumorigenesis process 
[39]. The pathways involved in cellular senescence exhibit several levels 
of regulation with redundancy between the different levels. Moreover, 
signal transduction through canonical signaling pathways, additional 
layers of regulation by miRNAs and methylation have been recently 
discovered [50,51]. The shortening of telomeres has been proposed 
to be the “clock” responsible for counting divisions in human cells 
and limits the number of duplications [52]. In general, most tumors 
contain telomeres elongated by telomerase activity, which allows the 
constitutive elongation of telomeres. Telomerase activity is essential 
for replicative immortality in humans but not in most murine models 
[42]. Cellular senescence can also be elicited by other types of stress, 
including oncogenic, redox, and DNA-damage stresses, but in these 
cases, the establishment of cellular senescence is also independent of 
telomerase [53].
Senescence dynamics show two different stages: cell cycle arrest 
and the subsequent acquisition of senescence characteristics, including 
proliferative permanent arrest (geroconversion). Senescence effector 
pathways converge to cell cycle arrest through the inhibition of 
CDKs. Therefore, most of the pathways that are known to influence 
senescence affect the cell cycle, either directly or indirectly. The best 
known effector pathways are the p16INK4a/pRB, the p19ARF/p53/
p21CIP1, and the PI3K/mTOR/FOXO pathways [54-57], which show 
a high degree of interconnection. Additionally, two routes have been 
proposed to be responsible for geroconversion. These include the pRb 
pathway and the mTOR pathway [58-62]. If the senescence program 
is not activated, the cell stops proliferating but retains the ability to 
resume growth once the limiting factors have been eliminated [58,59]. 
It has also been shown that if the mTOR pathway is activated, arrest 
is permanent and the cell enters senescence [63]. This can also be 
achieved by producing permanent changes in chromatin, especially in 
E2F transcription sites, which block the transcription of genes involved 
in proliferation [64]. Permanent inactivation of pRb, perhaps with the 
contribution of phosphatases [61] has been shown to give the signal 
for the recruitment of different mufflers to heterochromatin. Human 
cells show heterochromatin compaction during senescence (SAHF, 
senescence associated heterochromatin foci dependent of the pRb 
pathway) [64]. These SAHFs stabilize gene silencing, cause cell cycle 
arrest and appear to be crucial for the stability of the permanent stop 
during senescence. Mutations in these effector pathways extend the 
cellular lifespan and contribute to immortality in tumors.
Genetic experiments have contributed to understanding why 
oncogenic signals need to bypass this barrier to induce tumors and have 
identified which proteins may be involved in immortalization [6,43,65]. 
The absence of p53 function induced by dominant negative mutants, 
specific p53 shRNAs, antisense mRNA, oligonucleotides, or viral 
oncoproteins (such as SV40 T antigen or HPV16 E6) is sufficient to 
substantially extend the lifespan of several cell types in culture [66-68]. 
Likewise, the alteration of p53regulators may extend the lifespan to an 
extent similar to p53 loss. p33ING1, MDM2, p14ARF, the PML tumor 
suppressor, and the cyclin-dependent kinase (CDK) inhibitor p21WAF1 
have been related to p53, and their alterations bypass senescence (see 
[66-68] and references therein). The retinoblastoma tumor suppressor 
pathway, pRb, and its regulators have also been related to senescence. 
Species Spontaneous Carcinogen exposure*
Human 10-10 10-6/-7
Mouse 10-5 10-3/-4
Rat 10-6 10-4
Syrian hamster 10-9 10-6/-7
Chinese hamster 10-6 10-4
Table 1: Relative propensities of fibroblasts from different mammalian species to 
spontaneous- or carcinogen-induced immortalization.
*The efficacy of carcinogen-induced immortalization is dependent on the specific 
carcinogen and the doses. Here, an estimation of immortalization efficacy for a 
variety of carcinogens and doses is provided.
Agent Mechan™ism Cell type Reference
Ionizing radiation DNA-DamageOxidative stress
Primary,
Tumor cells [18,30]
H2O2 Oxidative stress Primary [31]
Na Butirate Epigenetic silencing Primary,Tumor cells [32]
Cisplatin, doxorubicin, 
aphidicolin, etoposide, 
citarabine, BrDU
DNA-damage
Oxidative stress
Primary,
Tumor cells
[18]
[30,23]
Retinoids Differentiating agent Primary,Tumor cells [33,34]
Taxol, vincristine Microtubule targeting Primary,Tumor cells [18,30]
Table 2: Agents inducing senescence.
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CDK inhibitors, such as the INK4 family, E2F factor, BMI1, PP1a, Spn, 
and TBX2, and viral oncoproteins, such as E7, SV40 large T antigen, 
and E1A, have been shown to contribute to senescence [35,69,70]. 
Other pathways such as the PI3K/FoxO/mTOR pathway also have been 
strongly related to cellular senescence and with aging in many species 
[58,59,71,72]. A variety of models have been used to identify and study 
senescence/immortalization genes and pathways. To that end, the 
application of functional screenings to mammalian cells undergoing 
senescence has led to the identification of new regulatory pathways 
impinging on new physiological processes. Using primarily genetic 
screenings [73-77] as well as transcriptomics, miRNA deregulation 
analysis, and whole exome sequencing, many other genes have been 
shown to contribute to a senescence-like phenotype including PGM, 
IGFBP3 and IGFBPrP1], PAI-1, MKK3, MKK6, Smurf2, HIC-5, 
TBX2, BCL6, DRIL1, SAHH, PPP1A, Spn, KLF4, and CXCR2-binding 
chemokines, ([78] and references therein). Interestingly, all of these 
genes have been shown to be related to human tumorigenesis. 
In conclusion, there are many regulators of senescence and many 
more to be discovered, and alterations to these regulators might render 
cells immortal and therefore allow carcinogenesis. Thus, the full panel 
of molecular alterations induced by carcinogens should be studied. 
Furthermore, compounds targeting these proteins and providing 
cellular immortalization without leaving a structural or epigenetic 
footprint may exist. In this case, the design of more specific and 
physiological assays may be necessary to determine the relevance of 
environmental compounds that may alter the senescence program and 
decisively contribute to immortalization and tumorigenesis.
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